<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metabolic dysfunction-associated steatotic liver disease in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metabolic dysfunction-associated steatotic liver disease in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metabolic dysfunction-associated steatotic liver disease in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marialena Mouzaki, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stavra A Xanthakos, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth B Rand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3937066427"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD) [<a href="#rid1">1</a>], is the most common cause of liver disease in children [<a href="#rid2">2-4</a>]. MASLD is a steatotic liver disease that occurs in the setting of visceral adiposity, dyslipidemia, and/or insulin resistance.</p><p>MASLD ranges in severity from steatosis (increased liver fat without inflammation) to metabolic dysfunction-associated steatohepatitis (MASH; increased liver fat with inflammation and hepatocellular injury, with or without fibrosis)  (<a class="graphic graphic_picture graphicRef59170" href="/d/graphic/59170.html" rel="external">picture 1</a>). The natural history of MASH in children is not well described, but, in a subset of children, it may lead to fibrosis, cirrhosis, and, ultimately, liver failure in adulthood [<a href="#rid5">5-7</a>].</p><p>The clinical presentation, evaluation, and management of MASLD in children and adolescents are discussed below. Evaluation and management of other obesity-related comorbidities and the pathogenesis of MASLD are discussed separately. (See  <a class="medical medical_review" href="/d/html/5869.html" rel="external">"Overview of the health consequences of obesity in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/3596.html" rel="external">"Pathogenesis of nonalcoholic fatty liver disease"</a>.)</p><p class="headingAnchor" id="H2482954297"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>In July 2023, nomenclature and diagnostic criteria for steatotic liver disease were revised following an international Delphi consensus process [<a href="#rid8">8</a>]. The rationale for changing the nomenclature from NAFLD to MASLD was the desire to reduce potential stigma associated with the terms "nonalcoholic" and "fatty," better reflect the underlying pathophysiology of the disorder, and align the nomenclature with specific diagnostic criteria.</p><p>Secondary causes of steatotic liver disease, such as hepatitis C, parenteral nutrition, steatogenic medication (eg, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproate</a>), lipodystrophy, or inborn errors of metabolism must be considered in the differential diagnosis of MASLD, particularly in children who do not have typical cardiometabolic risk factors for MASLD [<a href="#rid9">9</a>].</p><p>MASLD is subdivided into categories, defined by histologic findings and level of alcohol intake  (<a class="graphic graphic_table graphicRef115653" href="/d/graphic/115653.html" rel="external">table 1</a>) [<a href="#rid1">1,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic dysfunction-associated steatotic liver disease (MASLD)</strong> – MASLD refers to steatotic (fatty) liver as determined by imaging or biopsy (&gt;5 percent hepatic steatosis) with at least one risk factor for cardiometabolic dysfunction including overweight/obesity/visceral adiposity, dysglycemia, hypertension, or dyslipidemia. Other causes of steatotic liver disease should still be excluded but, in some cases, can coexist with MASLD (eg, hepatitis C). Importantly, the diagnosis of MASLD does <strong>not</strong> require the presence of chronically elevated liver enzymes (which was previously a diagnostic criterion for NAFLD).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic dysfunction-associated steatohepatitis (MASH)</strong> – MASH is defined as MASLD plus inflammation and hepatocellular injury, such as ballooning of hepatocytes, with or without fibrosis. These diagnostic criteria are identical to nonalcoholic steatohepatitis (NASH) criteria, with no revisions in the 2023 nomenclature consensus paper. In children, a liver biopsy is required to make a definitive diagnosis of MASH because there are no validated, reliable noninvasive biomarkers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MASH with fibrosis or cirrhosis</strong> – This refers to cirrhosis or advanced fibrosis with current or previous histologic evidence of MASLD or MASH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MASLD and increased alcohol intake</strong> – This category refers to MASLD in the setting of increased alcohol intake; it is more common in adults but also applies to adolescents. This new category recognizes that steatotic liver disease can involve a combination of metabolic dysfunction and alcohol-related injury below the threshold of alcohol intake required for diagnosis of alcohol-related liver disease. Increased alcohol intake is defined as 140 to 350 g/week for females and 210 to 420 g/week for males. This range defines a spectrum between MASLD-predominant (at lower end of alcohol intake) and alcohol-predominant disease (at higher end).</p><p></p><p>Because MASLD was defined in 2023, the available data regarding epidemiology, risk factors, natural history, and treatment in children are based on the prior NAFLD definition, which primarily focused on children whose liver disease was identified because of chronically elevated liver enzymes. Concordance between NAFLD and MASLD diagnosis in children has not yet been evaluated. A European consortium of adults with NAFLD demonstrated a high concordance (98 percent) between MASLD and NAFLD diagnoses [<a href="#rid8">8</a>].</p><p><strong>Note:</strong> Until pediatric studies are available to determine the concordance between MASLD and NAFLD, we will maintain NAFLD nomenclature for historical studies that used the prior NAFLD definition to distinguish these from future studies that will use the newer MASLD definition and terminology.</p><p class="headingAnchor" id="H979198168"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H4028123101"><span class="h2">Prevalence and demographics</span><span class="headingEndMark"> — </span>The estimated population prevalence of NAFLD was most often based on indirect evidence of a steatotic liver, either using evidence of hepatic steatosis from imaging or elevations in serum aminotransferase levels in at-risk subjects. In contrast, MASLD is defined by either radiologic or biopsy evidence of steatosis in children with metabolic risk factors. No pediatric prevalence data using MASLD diagnostic criteria exist yet. As an example, there was a modest male predominance in the studies that used biochemistry to diagnose NAFLD but not in studies using ultrasound. Patients are typically diagnosed after nine years of age, in part because clinical practice guidelines recommend that screening begin around age 9 to 10 years. However, case reports describe steatosis developing earlier, including in utero [<a href="#rid11">11</a>], and cirrhosis developing as early as eight years [<a href="#rid10">10,12</a>].</p><p>Estimates of NAFLD or MASLD prevalence may vary by method of ascertainment, as well as the population studied (ie, referral, community, ethnic group), as illustrated by the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histology</strong> – In an autopsy study of 742 children and adolescents in San Diego County, the prevalence of steatotic liver disease was 9.6 percent overall and 38 percent in children with obesity [<a href="#rid13">13</a>]. Histologic steatohepatitis was seen in 23 percent of the subjects with steatotic liver, or 3 percent of the population overall. The prevalence of steatotic liver disease was strongly associated with race/ethnicity, independent of obesity: Hispanic youth had a fivefold increase in risk for steatotic liver as compared with Black youth, after adjustment for body mass index. White youth had intermediate levels of risk. Because this study used histologic measures of steatotic liver disease in an unselected population, it is the best representation of the prevalence of steatotic liver disease among children and adolescents in the United States. Another autopsy study conducted in New York City confirmed the relatively low rates of hepatic steatosis and steatohepatitis among Black children and adolescents compared with Hispanic or White children and adolescents [<a href="#rid14">14</a>]. However, this study found comparable rates of hepatic steatosis among Hispanic and non-Hispanic White individuals, which may be due to a higher proportion of Caribbean Hispanic ancestry and lower proportion of Mexican/Central American Hispanic ethnicity compared with the San Diego County region. Caribbean Hispanic ancestry is associated with a higher percentage of African genetic admixture that could be protective against hepatic steatosis [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminotransferase elevations</strong> – Historically, serum aminotransferase elevations were used as an indirect estimate of the prevalence of NAFLD in a population but had limited sensitivity and specificity for detection of steatosis [<a href="#rid16">16</a>]. Typically, the prevalence of hepatic steatosis is underestimated using aminotransferase elevations, but this depends in part on the alanine aminotransferase (ALT) threshold employed in the study.</p><p></p><p class="bulletIndent1">In a large population-based study in the United States (National Health and Nutrition Examination Survey 2011 to 2018), 16 percent of adolescents had elevated ALT (&gt;22 units/L for females and &gt;26 units/L for males) presumed to be NAFLD, rising to 39 percent of those with obesity [<a href="#rid17">17</a>]. In another large population-based study, 11 percent of all children had ALT above similar thresholds [<a href="#rid18">18</a>]. A meta-analysis estimated the prevalence of NAFLD by abnormal ALT (using various thresholds) to be 7 percent in the general population (9 studies) and 13.7 percent in children with obesity (14 studies) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrasound</strong> – Ultrasound has poor sensitivity and specificity for the detection of hepatic steatosis [<a href="#rid19">19</a>]. In a meta-analysis, the prevalence of hepatic steatosis was 7.6 percent in the general population (10 studies) and 41.3 percent in children with obesity (34 studies) [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H965469590"><span class="h2">Risk factors and comorbidities</span><span class="headingEndMark"> — </span>Historically, NAFLD was strongly associated with obesity in all age groups [<a href="#rid20">20,21</a>]. By definition, MASLD is also closely associated with elements of metabolic syndrome (abdominal fat distribution, insulin resistance, diabetes, dyslipidemia, and hypertension [<a href="#rid22">22-25</a>]). NAFLD was also associated with polycystic ovary syndrome and obstructive sleep apnea (OSA), independent of the degree of obesity [<a href="#rid9">9,26-28</a>]. Therefore, children with suspected or established MASLD should be evaluated for these comorbidities  (<a class="graphic graphic_table graphicRef65547" href="/d/graphic/65547.html" rel="external">table 2</a>) and receive counseling regarding healthy lifestyle to help reduce the risk of cardiovascular disease and type 2 diabetes mellitus. (See <a class="local">'Natural history'</a> below.)</p><p>Hepatic steatosis may occur in individuals without obesity, often accompanied by insulin resistance and dyslipidemia (consistent with a diagnosis of MASLD under the new nomenclature system), or it may occur in association with genetic disorders such as lipodystrophy syndromes [<a href="#rid29">29</a>]. Several single-nucleotide polymorphisms have been associated with increased risk of NAFLD; among lean children, genetic risk factors may be a stronger predictor of liver fat than cardiometabolic markers [<a href="#rid30">30,31</a>].</p><p>Other risk factors for NAFLD include maternal obesity during gestation [<a href="#rid32">32</a>], panhypopituitarism [<a href="#rid33">33</a>], sarcopenia or lower muscle mass [<a href="#rid34">34,35</a>], and Hispanic ethnicity (the latter noted in studies from the United States [<a href="#rid36">36,37</a>]). Reasons for the association with Hispanic ethnicity may include higher concentration of a genetic risk factor (predominantly <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609567&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaEUUI8vUBCVvTn9VTUPbo%2Be&amp;TOPIC_ID=115661" target="_blank"><i>PNPLA3</i></a> variants) in some Hispanic populations and/or differences in social drivers of health [<a href="#rid38">38</a>]. (See <a class="local">'Prevalence and demographics'</a> above.)</p><p class="headingAnchor" id="H1209078658"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>The natural history of pediatric NAFLD was illustrated by a study of 122 children with biopsy-confirmed NAFLD who were enrolled in the placebo arm of clinical trials and received standard-of-care lifestyle counseling [<a href="#rid39">39</a>]. After a median of 1.6 years of follow-up, repeat liver biopsy revealed:</p><p class="bulletIndent1"><span class="glyph">●</span>Borderline and definite nonalcoholic steatohepatitis (NASH) at baseline – Resolved to no NASH in 29 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NAFL or borderline NASH at baseline – Progressed to definite NASH in 18 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete resolution of NAFLD – Occurred in 2.4 percent (3 of 122 children, all of whom had NAFL but not NASH at baseline)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrosis – Improved in 34 percent and progressed in 23 percent</p><p></p><p>Clinical characteristics associated with disease progression/fibrosis worsening included baseline adolescent age, ALT, and total and low-density lipoprotein (LDL) cholesterol levels. Longitudinal predictors of disease progression were a rising ALT, gamma-glutamyl transpeptidase (GGTP), and hemoglobin A1c as well as the development of type 2 diabetes. These factors may help guide escalation to more intensive interventions and decisions regarding repeat liver biopsy (see <a class="local">'Follow-up'</a> below). Overall, 7 percent of the cohort developed incident type 2 diabetes within two years, at a cumulative incidence rate nearly 300-fold the rate of the general pediatric population.</p><p>A study from Sweden found that biopsy-confirmed NAFLD in children and young adults was associated with substantially higher mortality risk compared with population-based controls over 15 years of follow-up (adjusted hazard ratio [aHR] 5.9) [<a href="#rid40">40</a>]. The mortality risk was higher for NASH (aHR 11.5) compared with simple steatosis (aHR 5.3). Excess mortality derived from cancer (aHR 15.6), liver disease (aHR 16.5), and cardiovascular disease (aHR 4.3).</p><p>Natural history studies of children diagnosed using the revised MASLD criteria have not yet been published.</p><p class="headingAnchor" id="H735204496"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Most patients are asymptomatic [<a href="#rid20">20</a>]. A minority of children may complain of right upper quadrant pain or nonspecific symptoms such as abdominal discomfort and fatigue [<a href="#rid41">41,42</a>]. Other symptoms that have been reported in patients with the historical diagnosis of NAFLD, such as regurgitation, bloating, and musculoskeletal pain, are unlikely to be due to the condition itself. Instead, these symptoms may be related to other obesity-associated comorbidities such as gastroesophageal reflux disease, constipation, functional abdominal pain, or slipped capital femoral epiphysis [<a href="#rid43">43</a>]. In studies of children with NAFLD, signs of end-stage liver disease (such as palmar erythema, spider angiomata, muscle wasting, jaundice, or encephalopathy) have been rare because the disease has rarely progressed to decompensated cirrhosis during childhood.</p><p>On examination, acanthosis nigricans is common, reflecting the close association with insulin resistance/type 2 diabetes. Hepatomegaly and/or splenomegaly may be present but may be difficult to ascertain on physical examination if significant abdominal adiposity is present.</p><p>In studies of children with NAFLD, laboratory abnormalities typically include elevations in liver transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), alkaline phosphatase, and gamma-glutamyl transpeptidase (GGTP) [<a href="#rid3">3,12,20,44,45</a>]. These abnormalities may resolve or improve in children with overweight or obesity who are able to reach a healthier weight and body composition through lifestyle or other measures [<a href="#rid44">44,46</a>]. In some cohorts with historical NAFLD diagnosis, serum aminotransferase concentrations were normal in a significant minority (up to 25 percent in some studies [<a href="#rid47">47</a>]); therefore, the new definition of MASLD does not include elevated liver enzymes as a diagnostic criterion [<a href="#rid48">48</a>]. Aminotransferase concentrations may also decline in the setting of cirrhosis. Although GGTP could be normal or elevated in children with NAFLD, <strong>isolated</strong> elevations of GGTP may suggest an alternate diagnosis, such as primary sclerosing cholangitis, excess alcohol intake, or a side effect of a medication (eg, antiepileptic medications).</p><p class="headingAnchor" id="H2521491350"><span class="h1">SCREENING</span></p><p class="headingAnchor" id="H2806580088"><span class="h2">Serum alanine aminotransferase (recommended)</span><span class="headingEndMark"> — </span>Historically, screening for NAFLD consisted of measuring serum alanine aminotransferase (ALT), as summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef117904" href="/d/graphic/117904.html" rel="external">algorithm 1</a>) [<a href="#rid9">9</a>]. Under the new MASLD criterion, imaging or biopsy evidence of steatosis is the key definition, but updated guidance for screening is not yet available. Until new screening guidelines are developed, we continue to suggest screening with ALT because this strategy will help to identify the subset of children with MASLD who are at increased risk for more severe disease (eg, metabolic dysfunction-associated steatohepatitis/nonalcoholic steatohepatitis [MASH/NASH]), even if it fails to identify the subset of children with hepatic steatosis who have normal liver enzymes.</p><p>The 2017 guideline from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition recommended screening with ALT alone [<a href="#rid9">9</a>]. The 2012 European Society for Paediatric Gastroenterology, Hepatology and Nutrition guideline recommended screening with both ALT and imaging, recognizing that some children with hepatic steatosis have normal liver enzymes [<a href="#rid47">47,49</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Screen all children with obesity (body mass index ≥95<sup>th</sup> percentile); screen overweight children (body mass index ≥85<sup>th</sup> percentile) if other risk factors are present (eg, signs of insulin resistance or a family history of NAFLD or MASLD). Begin screening between 9 and 11 years of age. Screening can be considered at a younger age if there are strong risk factors for MASLD. (See <a class="local">'Risk factors and comorbidities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ALT interpretation</strong> – For serum ALT interpretation, we suggest using the following upper limit of normal (ULN):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adolescents 12 to 17 years:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Girls – 22 units/L</p><p class="bulletIndent3"><span class="glyph">-</span>Boys – 26 units/L</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children 1 to &lt;12 years – 30 units/L</p><p></p><p class="bulletIndent1">Note that these values are substantially lower than the ULNs reported in most pediatric hospital laboratories.</p><p></p><p class="bulletIndent1">The cutoffs for adolescents represent the 97<sup>th</sup> percentiles for a healthy lean population, as determined from the National Health and Nutrition Examination Survey for adolescents 12 to 17 years old [<a href="#rid50">50</a>]. Use of these thresholds is supported by a separate study from Germany, which reported comparable ULNs, although somewhat higher thresholds in younger children and a transient rise peripubertally [<a href="#rid51">51</a>]. For younger children, our suggestion for a ULN ALT threshold (30 units/L) is derived from the CALIPER study [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Next steps</strong> – Subsequent steps depend on the degree and duration of ALT elevation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with normal ALT results, repeat screening in one to three years (or sooner in children with increasing obesity or other risk factors), while providing counseling to promote a healthy body weight.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with moderate ALT elevations (ALT &gt;ULN but &lt;80 units/L), repeat the measurement of serum ALT within a few months. If ALT remains elevated, intensify counseling on diet and exercise to achieve weight loss.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with ALT that is persistently &gt;2 × ULN (ie, &gt;44 units/L for adolescent girls and 52 units/L for boys) for three or more months, refer to a gastroenterologist for a full evaluation, as described below.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other indications for further evaluation include ALT elevations &gt;80 units/L (on two occasions), signs or symptoms of acute liver disease, or red flags for advanced liver disease, as described below. (See <a class="local">'Indications'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with elevated ALT and symptoms of an acute infection (fever, vomiting, diarrhea, pharyngitis, etc), measure ALT again two to four weeks after resolution of the illness to verify if the ALT elevation persists, before initiating further evaluation. Similarly, for asymptomatic patients with more marked acute liver enzyme elevations (&gt;10 × ULN), repeat the test two weeks later rather than initiating a more extensive evaluation. Many viral illnesses, including influenza, Epstein-Barr virus, cytomegalovirus, influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and others, can be associated with mild to marked liver enzyme elevations, and some of these infections can be asymptomatic.</p><p></p><p class="bulletIndent1">The timing and pace of the evaluation should also be influenced by the presence of other clinical risk factors, such as the degree of obesity, signs of insulin resistance, ethnicity (eg, Hispanic children have higher risk [<a href="#rid53">53</a>]), comorbidities such as type 2 diabetes or obstructive sleep apnea (OSA), or clinical symptoms or signs of more advanced liver disease [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limitations</strong> – Although serum ALT is recommended as the primary screening test for identifying children at higher risk of significant MASLD, it historically has had variable sensitivity and specificity for detecting clinically significant liver disease, depending on the ALT threshold used. In one study of children with overweight and obesity, ALT &gt;2 × ULN had a sensitivity of 88 percent and specificity of 26 percent for detecting NAFLD on liver biopsy [<a href="#rid16">16</a>]. A higher threshold of ALT &gt;80 units/L had a sensitivity of 57 percent and specificity of 71 percent. In a large study of children and adolescents with suspected NAFLD who underwent liver biopsy, fibrosis was seen in 12 percent of those with normal ALT and in 54 percent of those with mildly elevated ALT (defined as ALT 26 to 50 units/L in boys and 23 to 44 units/L in girls) [<a href="#rid55">55</a>]. Advanced fibrosis (bridging fibrosis or cirrhosis) was seen in none of the children with normal ALT, 9 percent of those with mildly elevated ALT, and 15 percent of those with significantly elevated ALT (defined as ALT ≥50 units/L in boys and ≥44 units/L in girls). Thus, the degree of ALT elevation helps to predict the histologic degree of fibrosis.</p><p></p><p class="headingAnchor" id="H1021446646"><span class="h2">Ultrasonography</span><span class="headingEndMark"> — </span>Whether ultrasound should be used as part of screening for MASLD is uncertain. Although ultrasound can detect the presence of hepatic steatosis, indicated by increased echogenicity, the sensitivity and specificity for detecting clinically significant liver disease are poor [<a href="#rid9">9,56,57</a>]. Screening at-risk children with overweight or obesity with ultrasonography was recommended in the 2012 European NAFLD guidelines but not in the 2017 North American guidelines [<a href="#rid9">9,49</a>]. Until further data are available, we do not use ultrasound as a <strong>screening</strong> tool for MASLD. However, we do include it as part of the <strong>further</strong> <strong>evaluation</strong> for individuals with elevated liver enzymes to evaluate for structural abnormalities and to help assess the severity of liver disease [<a href="#rid9">9,19</a>]. (See <a class="local">'Imaging'</a> below.)</p><p class="headingAnchor" id="H1554269154"><span class="h1">FURTHER EVALUATION</span></p><p class="headingAnchor" id="H2904083529"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Indications for further evaluation are  (<a class="graphic graphic_algorithm graphicRef117904" href="/d/graphic/117904.html" rel="external">algorithm 1</a>) [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Alanine aminotransferase (ALT) &gt;2 × upper limit of normal (ULN), ie, &gt;44 units/L for girls or &gt;52 units/L for boys, for more than three months [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ALT &gt;80 units/L on at least two occasions and in the absence of symptoms of acute infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs or symptoms suggesting acute liver disease (rather than MASLD), including fever, right upper quadrant tenderness, jaundice, or dark urine (bilirubinuria).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs and symptoms that may indicate advanced liver disease include gastrointestinal bleeding, jaundice, splenomegaly, firm liver edge, enlarged left lobe, encephalopathy manifesting as chronic fatigue and/or declining school performance. In addition, for children with persistently or acutely elevated liver enzymes, the evaluation should include a full liver profile, complete blood cell count, and prothrombin time. Signs of decompensated cirrhosis include low platelets or white blood cell count, elevated direct bilirubin, or elevated international normalized ratio, but this is rare in children with MASLD.</p><p></p><p class="headingAnchor" id="H965540524"><span class="h2">History</span><span class="headingEndMark"> — </span>Patients with suspected MASLD typically have no symptoms of liver disease. Their symptoms, if any, usually are secondary to complications of obesity (eg, knee/groin pain due to slipped capital femoral epiphysis, intermittent right upper quadrant abdominal pain secondary to gallstones, regurgitation due to gastroesophageal reflux disease, or headaches secondary to increased intracranial pressure). (See  <a class="medical medical_review" href="/d/html/5869.html" rel="external">"Overview of the health consequences of obesity in children and adolescents"</a>.)</p><p>In addition, it is particularly important to identify signs and symptoms of the following comorbid conditions, each of which may contribute to the development or worsen the severity of steatotic liver disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroidism – Symptoms may include cold intolerance and recent weight gain. In children whose epiphyses have not fused, an important sign is declining height velocity. (See  <a class="medical medical_review" href="/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive sleep apnea (OSA) – Suggested by persistent snoring, pauses in breathing, nocturnal enuresis, and early morning fatigue or headaches. (See  <a class="medical medical_review" href="/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type 2 diabetes – Symptoms may include polyuria, polydipsia, or unexplained weight loss, although many patients are asymptomatic. (See  <a class="medical medical_review" href="/d/html/5820.html" rel="external">"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depression/anxiety – Mental health issues are prevalent in this population and may affect the patient's ability to implement the recommended lifestyle interventions [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol and drugs – Evaluate specifically for alcohol use and the possibility of hepatotoxic drugs (especially anticonvulsant medications and certain antimicrobials). (See  <a class="medical medical_review" href="/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history – Evaluate the family history for liver disease (eg, MASLD/NAFLD, autoimmune conditions, Wilson disease, cryptogenic cirrhosis, or liver transplantation) and cardiometabolic disease (type 2 diabetes, heart disease, or stroke).</p><p></p><p class="headingAnchor" id="H4248593059"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination is focused on identifying the following  (<a class="graphic graphic_table graphicRef116583" href="/d/graphic/116583.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Height, weight, and body mass index. (See  <a class="medical medical_review" href="/d/html/5861.html" rel="external">"Clinical evaluation of the child or adolescent with obesity", section on 'Body mass index'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for MASLD (abdominal fat distribution, acanthosis nigricans).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs of comorbid conditions or other causes of hepatic steatosis, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Declining height velocity or delayed or accelerated pubertal development – Suggests hypothyroidism or multiple pituitary hormone deficiencies. (See  <a class="medical medical_review" href="/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acanthosis nigricans – Suggests insulin resistance, which may be associated with diabetes risk or polycystic ovary syndrome. Hirsutism is another common feature of polycystic ovary syndrome. Unexplained weight loss, sometimes with polyuria and polydipsia, can also be a sign of new-onset diabetes. (See  <a class="medical medical_review" href="/d/html/5852.html" rel="external">"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal fat distribution – Loss of subcutaneous adipose tissue, sometimes with apparent accumulation of fat in other regions of the body, raises the possibility of a lipodystrophic syndrome. (See  <a class="medical medical_review" href="/d/html/1788.html" rel="external">"Lipodystrophic syndromes"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatomegaly and/or splenomegaly – Splenomegaly raises the possibility of cirrhosis (with portal hypertension), while hepatosplenomegaly may be secondary to underlying storage disease or lysosomal acid lipase deficiency. (See  <a class="medical medical_review" href="/d/html/2936.html" rel="external">"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features", section on 'Organomegaly'</a> and <a class="local">'Tests to exclude other liver diseases'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs suggesting end-stage liver disease (eg, jaundice, palmar erythema, edema, spider angiomata, or asterixis). End-stage liver disease has historically been rare in pediatric patients with MASLD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated systolic and diastolic blood pressure, measured with an appropriately sized cuff. (See  <a class="medical medical_review" href="/d/html/6088.html" rel="external">"Evaluation of hypertension in children and adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H1822928503"><span class="h2">Laboratory evaluation</span></p><p class="headingAnchor" id="H455994660"><span class="h3">Routine laboratory testing</span></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ALT, aspartate aminotransferase (AST), alkaline phosphatase, gamma-glutamyl transpeptidase (GGTP), total and direct bilirubin, albumin</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for cardiometabolic risk factors (included in criteria required for diagnosis of MASLD  (<a class="graphic graphic_table graphicRef115653" href="/d/graphic/115653.html" rel="external">table 1</a>))</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemoglobin A1c and/or fasting glucose</p><p class="bulletIndent2"><span class="glyph">•</span>Fasting lipid panel (triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein [LDL] cholesterol)</p><p></p><p class="headingAnchor" id="H2580557200"><span class="h3">Testing for additional comorbid conditions</span><span class="headingEndMark"> — </span>Children and adolescents with MASLD should be screened for other comorbidities associated with overweight and obesity, including dyslipidemia, hypertension, type 2 diabetes, renal impairment, polycystic ovary syndrome, and OSA  (<a class="graphic graphic_table graphicRef65547" href="/d/graphic/65547.html" rel="external">table 2</a>). Screening and management are the same as for other children with obesity. However, screening is particularly important in children with MASLD due to the clustering of these comorbidities among children with obesity. (See  <a class="medical medical_review" href="/d/html/5861.html" rel="external">"Clinical evaluation of the child or adolescent with obesity", section on 'Initial management'</a>.)</p><p>An increased prevalence of chronic kidney disease has been associated with NAFLD in children and adults [<a href="#rid59">59,60</a>]. We therefore suggest annual screening with serum blood urea nitrogen and creatinine as well as urine albumin-to-creatinine ratio to detect early injury and allow early intervention [<a href="#rid61">61</a>]. This is particularly relevant for children who have concomitant conditions associated with higher risk of developing chronic kidney disease, including severe obesity, hypertension, and diabetes. (See  <a class="medical medical_review" href="/d/html/5826.html" rel="external">"Chronic complications and screening in children and adolescents with type 2 diabetes mellitus", section on 'Screening'</a>.)</p><p>Although several studies have suggested a risk of decreased bone mineral density in children with NAFLD, particularly those with nonalcoholic steatohepatitis (NASH), the degree of reduction is mild and of unclear long-term clinical significance [<a href="#rid62">62</a>]. Therefore, we do not recommend routine dual-energy x-ray absorptiometry screening for osteopenia.</p><p class="headingAnchor" id="H4039747993"><span class="h3">Tests to exclude other liver diseases</span><span class="headingEndMark"> — </span>The differential diagnosis of moderate aminotransferase elevations with evidence of steatotic liver on imaging is outlined in the table  (<a class="graphic graphic_table graphicRef116582" href="/d/graphic/116582.html" rel="external">table 4</a>). Testing is recommended because some of these disorders require specific treatment, including celiac disease, autoimmune hepatitis, hemochromatosis, viral hepatitis, and Wilson disease. Particularly in younger children (&lt;5 years of age) or in those without overweight or obesity, there should be increased suspicion for causes other than MASLD, such as inborn errors of metabolism.</p><p>The yield of screening for these disorders has historically varied in different cohorts of children with NAFLD. In a cohort of 900 children referred for suspected NAFLD, only 2 percent were diagnosed with another disorder that caused or contributed to the liver disease [<a href="#rid63">63</a>]. Substantially higher yield was found in a separate single-center cohort, in which the prevalence of alternate diagnoses was 18 percent, most commonly autoimmune hepatitis (4 percent) [<a href="#rid16">16</a>]. Future studies using the new definitions of MASLD will be needed to determine the prevalence of alternate diagnoses.</p><p>For all patients with persistent elevations in ALT &gt;2 × ULN, we suggest the following tests  (<a class="graphic graphic_algorithm graphicRef117904" href="/d/graphic/117904.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral hepatitis</strong> – Anti-hepatitis C antibodies, hepatitis B surface antigen, and tests for other chronic viral infections if indicated by the history.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac disease</strong> – Tissue transglutaminase and total immunoglobulin A (IgA). (See  <a class="medical medical_review" href="/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'Non-gastrointestinal manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypothyroidism</strong> – Thyrotropin and free thyroxine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune hepatitis</strong> – Anti-nuclear antibodies, anti-liver/kidney microsomal antibodies, anti-smooth muscle antibodies, and total protein and IgG level. Of note, positive serum autoimmune antibodies have been reported in approximately 20 percent of children and adults with NAFLD [<a href="#rid64">64-66</a>]. Therefore, low-positive titers (eg, anti-nuclear antibodies 1:40) do not exclude the diagnosis of MASLD, but patients with high-positive titers should be further evaluated for the possibility of autoimmune hepatitis [<a href="#rid10">10</a>]. High globulins or increased total protein-to-albumin ratio also support the possibility of autoimmune hepatitis. (See  <a class="medical medical_review" href="/d/html/3665.html" rel="external">"Overview of autoimmune hepatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wilson disease</strong> – The minimum screen for Wilson disease is to measure serum ceruloplasmin levels. In addition, for patients with signs or symptoms that increase suspicion for this disorder (eg, low ceruloplasmin, marked elevations in AST and ALT, especially with elevated AST:ALT ratio, or neurologic or psychiatric symptoms), include a 24-hour urine collection for copper excretion.<em> </em>If performing a liver biopsy, a hepatic tissue concentration of copper can be quantified. (See  <a class="medical medical_review" href="/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-1 antitrypsin deficiency</strong> – Screen for this disorder by measuring serum alpha-1 antitrypsin levels or "PI" typing/phenotype. PI phenotypes associated with liver disease are ZZ or SZ. Heterozygotes (MZ or MS) do not have overt alpha-1 antitrypsin-related liver disease, but the genotype may contribute to the severity of their MASLD [<a href="#rid67">67,68</a>]. (See  <a class="medical medical_review" href="/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency", section on 'Hepatic disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monogenetic liver diseases associated with hepatic steatosis</strong> – For selected patients, such as those with early onset of liver disease (eg, preschool age), evidence of steatotic liver in the context of a lean phenotype, significant dyslipidemia, or other atypical features, we also screen for the following conditions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lysosomal acid lipase deficiency</strong> (cholesteryl ester storage disease; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F278000&amp;token=87jLzclRwWxNoI%2BQq5Gg74ZQlR%2BcogWr9WYcwQp%2F1Tz0wrkNoJJ4UIC8XdQTwhfc&amp;TOPIC_ID=115661" target="_blank">MIM #278000</a>) – Screen for this disorder in any patient with hepatosplenomegaly, prepubertal evidence of advanced liver fibrosis or cirrhosis, xanthelasma, or family history of unexplained hepatic dysfunction or early-onset cardiovascular disease [<a href="#rid69">69-74</a>]. Due to the steatotic liver, some patients with lysosomal acid lipase deficiency are misdiagnosed as having MASLD or another storage disease (Gaucher or Niemann-Pick). Patients with lysosomal acid lipase deficiency tend to have greater elevations of serum LDL compared with patients with MASLD and develop premature atherosclerosis [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent2">Lysosomal acid lipase deficiency can be diagnosed using an enzyme-based biochemical test [<a href="#rid75">75</a>]. A list of laboratories that perform this test can be accessed through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=115661" target="_blank">Genetic Testing Registry</a> website. Treatment with <a class="drug drug_pediatric" data-topicid="108897" href="/d/drug information/108897.html" rel="external">sebelipase alfa</a> leads to improved aminotransferases, hepatic steatosis, and lipid profiles, and the drug is now approved for use in the United States and several other countries [<a href="#rid76">76-81</a>].</p><p></p><p class="bulletIndent2">A fulminant infantile form, known as Wolman disease, is characterized by hepatosplenomegaly, hepatic fibrosis, failure to thrive, and adrenal calcifications or insufficiency. (See  <a class="medical medical_review" href="/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children", section on 'Defects in cholesterol biochemistry'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Abeta/hypobetalipoproteinemia</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F615558&amp;token=87jLzclRwWxNoI%2BQq5Gg78fTRc5CnbZ9KbpxyAodtFd1kQAjFFz7AqL%2BD9iZ%2BBNX&amp;TOPIC_ID=115661" target="_blank">MIM #615558</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F605019&amp;token=87jLzclRwWxNoI%2BQq5Gg72TXyUrl8OiaygHdkX6Qs98mrA71Cqa%2BrZ8zaxHmx%2B10&amp;TOPIC_ID=115661" target="_blank">MIM #605019</a>) – These disorders are suggested by the findings of low triglycerides and undetectable or low LDL on a lipid profile; other laboratory findings include low fat-soluble vitamin levels (due to fat malabsorption) [<a href="#rid82">82</a>]. Abetalipoproteinemia (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F200100&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FdmBbpmnnk6kMvbXjObw6Vv6vJINjtPN%2BXiE%2B9UmbEg&amp;TOPIC_ID=115661" target="_blank">MIM #200100</a>) typically presents in infancy with more severe symptoms including steatorrhea, failure to thrive, and progressive neurologic complications; this would be an unlikely cause of steatotic liver in an older child with obesity. If the results of these tests are concerning for these conditions, lipoprotein electrophoresis or genetic testing can be used to confirm the diagnosis. A list of laboratories that perform these tests can be accessed through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=115661" target="_blank">Genetic Testing Registry</a> website. (See  <a class="medical medical_review" href="/d/html/107473.html" rel="external">"Low LDL-cholesterol: Etiologies and approach to evaluation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lipodystrophy</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F608594&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2Bmgx2XPSKcvmkpC98pPyfgCaHg0%2B24IoKPuWGScnZoF&amp;TOPIC_ID=115661" target="_blank">MIM #608594</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F151660&amp;token=87jLzclRwWxNoI%2BQq5Gg7zZsyRogL9YM9wmc3Q0fNukoe8ZNZ6oKZP7lpXiwtvuo&amp;TOPIC_ID=115661" target="_blank">MIM #151660</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F269700&amp;token=87jLzclRwWxNoI%2BQq5Gg70%2FEMBfYrG%2FE4u%2FTOBeE3DJsPft%2BNMbZh3xoPqIlYkAX&amp;TOPIC_ID=115661" target="_blank">MIM #269700</a>) – When lipodystrophy is suspected based on physical examination findings of abnormal fat distribution and steatotic liver in the context of a lean body habitus, insulin resistance, and dyslipidemia, refer to genetics for further workup. (See  <a class="medical medical_review" href="/d/html/1788.html" rel="external">"Lipodystrophic syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monogenic obesity</strong> – For patients with marked hyperphagia and/or early-onset (eg, in infancy) severe (class II to III) obesity, genetic testing for monogenic causes of obesity may be appropriate. Though not a specific cause of MASLD, these patients may be at higher risk of MASLD and the genetic diagnosis may inform treatment options. (See  <a class="medical medical_review" href="/d/html/5861.html" rel="external">"Clinical evaluation of the child or adolescent with obesity", section on 'Tests for selected patients'</a>.)</p><p></p><p>A general approach to evaluating a patient with abnormal liver biochemistries is presented separately. (See  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p class="headingAnchor" id="H55359566"><span class="h2">Imaging</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrasound</strong> – We suggest performing liver ultrasound as part of the full <strong>evaluation</strong> in a child with chronically elevated liver enzymes. The main purpose is to evaluate for liver or biliary abnormalities, particularly if the history and physical examination suggest the presence of gallbladder disease or complications such as portal hypertension (eg, splenomegaly).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnetic resonance imaging (MRI)</strong> – MRI provides a more accurate quantitative measure of steatosis than does ultrasound, particularly in individuals with severe obesity [<a href="#rid83">83-85</a>]. However, it is not useful for screening for clinically important MASLD, because the severity of hepatic steatosis does not correlate with clinical features of advanced MASLD (eg, presence of steatohepatitis, fibrosis, etc) [<a href="#rid42">42,56,86,87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methods to assess fibrosis severity</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vibration-controlled transient elastography (eg, FibroScan)</strong> – This point-of-care ultrasound technique shows some promise in noninvasively assessing the severity of hepatic steatosis and fibrosis [<a href="#rid88">88-92</a>]. However, the technique has limited ability to distinguish between early stages of the disease and further validation studies are needed to determine its accuracy in pediatric cohorts diagnosed using MASLD criteria.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hepatic steatosis is reflected in the Controlled Attenuation Parameter (CAP) score. In a study of children with biopsy-confirmed NAFLD, a CAP score of ≥259 strongly correlated with steatosis grade (area under the curve 0.98 for distinguishing any steatosis from no steatosis) [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hepatic fibrosis is correlated with measures of liver stiffness (in kPA). In a North American cohort of 116 children with NAFLD, liver stiffness differentiated those with Ishak stage fibrosis 0 to 2 from those with stages 3 to 6 (area under the curve 0.70) [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ultrasound shear wave elastography</strong> – Ultrasound-based (eg, acoustic radiation force impulse) shear wave elastography correlates with significant fibrosis in pediatric patients with NAFLD, but this modality is limited by higher technical failure rates in patients with obesity [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Magnetic resonance elastography</strong> – This is a noninvasive approach to evaluate liver stiffness. It can detect advanced fibrosis, with overall accuracy of 89 to 90 percent, negative predictive value of 95 to 96 percent, and positive predictive value of 29 to 30 percent [<a href="#rid93">93-95</a>]. However, the technique is not able to discriminate well between no fibrosis versus mild fibrosis and its ability to detect inflammation has not been established [<a href="#rid96">96</a>]. Further, high cost, lack of widespread availability, and need for further validation of appropriate cutoff values render it inappropriate for routine screening of MASLD [<a href="#rid93">93</a>].</p><p></p><p>These tools may also be useful noninvasive measures to follow disease progression [<a href="#rid94">94</a>] but require further validation in longitudinal cohort of children with MASLD to determine optimum thresholds for detecting progression in fibrosis, as well as optimal populations, as some of the techniques have higher failure rates as severity of obesity worsens. (See  <a class="medical medical_review" href="/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults", section on 'Radiographic examinations'</a>.)</p><p class="headingAnchor" id="H3774650437"><span class="h2">Liver biopsy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Indications for liver biopsy in patients with suspected MASLD have not been established, and practice varies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Arguments in favor of performing a liver biopsy are that it is the most accurate approach to assess severity, particularly the presence and extent of inflammation and fibrosis [<a href="#rid3">3,9</a>]. If the liver biopsy identifies metabolic dysfunction-associated steatohepatitis (MASH), more intensive weight loss interventions (eg, consideration of obesity pharmacotherapy or weight loss surgery) and close monitoring are warranted. Furthermore, the liver biopsy is sometimes required to identify an alternate cause, such as autoimmune hepatitis or drug-induced liver injury.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Arguments against liver biopsy are that it is invasive and the results most often confirm the presence of MASLD and do not inform management, because there is no approved treatment for MASLD other than weight loss interventions.</p><p></p><p class="bulletIndent1">Therefore, the decision about whether to perform a liver biopsy should be made on a case-by-case basis, after discussion of the benefits and risks with the patient and their family. In our practice, we generally suggest a liver biopsy for patients with the following features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical features that are associated with more severe or progressive liver disease, such as ALT persistently &gt;80 units/L or splenomegaly, thrombocytopenia, or increased liver stiffness by elastography, particularly in patients with prediabetes or diabetes or significant dyslipidemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with severe obesity who are candidates for weight loss surgery but are undecided about whether to proceed. (See  <a class="medical medical_review" href="/d/html/5880.html" rel="external">"Surgical management of severe obesity in adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with features that suggest an alternate or additional cause of the liver disease for which liver biopsy would be useful or essential to confirm the diagnosis (such as autoimmune hepatitis).</p><p></p><p class="bulletIndent1">(See  <a class="medical medical_review" href="/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation of results</strong> – If biopsy is performed, the histologic features of MASLD include steatosis, which, if concurrently present with lobular or portal inflammation and ballooning degeneration of hepatocytes, is consistent with MASH. Fibrosis indicates more significant disease, particularly if stage 2 or higher  (<a class="graphic graphic_picture graphicRef59170" href="/d/graphic/59170.html" rel="external">picture 1</a>). Cirrhosis has been rare in pediatric NAFLD studies.</p><p></p><p class="bulletIndent1">Compared with older adolescents or adults, children in the early phases of puberty often display unique histopathologic features, including portal inflammation and portal fibrosis in the absence of hepatocellular ballooning; this histologic pattern has historically been called "type 2" or borderline zone 1 NASH, while the pattern typically seen in adults (steatosis with lobular inflammation and ballooning degeneration) has been called "type 1" or definite NASH  (<a class="graphic graphic_table graphicRef115653" href="/d/graphic/115653.html" rel="external">table 1</a>) [<a href="#rid10">10,97,98</a>].</p><p></p><p class="headingAnchor" id="H236518326"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnosis and categorization of MASLD involves these steps:</p><p class="bulletIndent1"><span class="glyph">●</span>MASLD should be suspected in a child with typical clinical features (obesity or cardiometabolic risk factors) and evidence of steatosis by imaging or biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children with one or more of the above features, a diagnosis of MASLD can be made by excluding other causes of liver disease through a focused history, physical examination, and laboratory/imaging evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A definitive diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) can only be made by liver biopsy, but this is not always necessary for clinical management (see <a class="local">'Liver biopsy'</a> above). The decision to perform a liver biopsy depends on the degree and persistence of alanine aminotransferase (ALT) elevation and whether there are any atypical features that raise the possibility of another form of liver disease.</p><p></p><p class="headingAnchor" id="H2859986651"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Available data on management and outcomes was derived from studies of children diagnosed with NAFLD or nonalcoholic steatohepatitis (NASH).</p><p class="headingAnchor" id="H1955285969"><span class="h2">Weight loss-focused approaches</span><span class="headingEndMark"> — </span>Weight management has been the only established treatment for NAFLD and the primary treatment recommendation in guidelines from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the American Gastroenterological Association [<a href="#rid9">9,10</a>] Small nonrandomized studies in children with NAFLD have shown improvement in liver histology or aminotransferase activity after weight loss [<a href="#rid3">3,44,99-101</a>]. We anticipate that weight management approaches will also remain the foundation for treatment of MASLD in children, with the addition of adjunctive medications and/or weight loss surgery to help achieve a healthier metabolic status.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diet and exercise</strong> – The main approach is lifestyle modification, with emphasis on dietary changes, which can result in improvement of the steatotic liver disease as well as reduction in excess weight. No particular diet has been clearly shown to be superior to any other in the treatment of NAFLD, although avoidance of sugar-sweetened beverages is often recommended, based on supportive studies [<a href="#rid9">9</a>]. One open-label, randomized trial in a cohort of 40 adolescent males, predominantly Hispanic (95 percent), reported that a diet with low free sugars for eight weeks resulted in greater reduction in hepatic fat compared with usual diet (adjusted mean difference -6.23 percent, 95% CI -9.45 to -3.02) [<a href="#rid102">102</a>]. It is possible that these effects were mediated, in part, by weight loss since the subjects on the low-sugar diet lost more weight during the study compared with those consuming their usual diet (mean between-group difference -2 kg, 95% CI -3.3 to -0.8 kg). Notably, this differential weight loss in the intervention group occurred despite the fact that the intervention diet only restricted free sugar intake to &lt;3 percent of daily caloric intake but did not restrict total energy intake (in kcal), which did not decrease significantly during the eight-week period in the intervention group. Because the prescribed foods were given to the household during the study, these findings may not be generalizable to other populations treated with dietary counseling alone.</p><p></p><p class="bulletIndent1">Weight loss and/or weight maintenance in younger children are difficult to achieve but tend to be enhanced by family-based and patient-centered approaches and more intensive interventions [<a href="#rid103">103</a>]. These strategies are discussed separately. (See  <a class="medical medical_review" href="/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting"</a>.)</p><p></p><p class="bulletIndent1">Physical activity can be beneficial in reducing adiposity and improving body composition (reducing risk of relative sarcopenia, which has been associated with NAFLD severity). Similar to dietary changes, no type of exercise has been demonstrated to be superior in this context, but pediatric studies have been limited. In one study, physical activity improved NAFLD (as measured by alanine aminotransferase [ALT] elevations), independent of weight loss [<a href="#rid104">104</a>]. Activity targets are similar to those for weight management and include promoting unstructured and structured physical activity and limiting screen time. (See  <a class="medical medical_review" href="/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting", section on 'Counseling'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – Weight loss surgery may be appropriate in selected adolescents with severe obesity [<a href="#rid10">10</a>]. Surgically induced weight loss improves NAFLD in adults (resolution rates of up to 90 percent), and observational evidence suggests that this is also true for adolescents. (See  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Bariatric surgery'</a> and  <a class="medical medical_review" href="/d/html/5880.html" rel="external">"Surgical management of severe obesity in adolescents", section on 'Comorbidity improvement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications that target weight loss and metabolic improvement</strong> – Medications that target weight loss are increasingly available and may have indirect benefits on MASLD. These include glucagon-like peptide 1 receptor (GLP-1) agonists (also approved for use in adolescents with type 2 diabetes) and phentermine-topirimate, which have not been studied as specific treatments for NAFLD or MASLD in youth but have shown benefit in studies in adults with NAFLD. The evidence and other considerations are discussed separately. (See  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Potential pharmacologic therapies'</a> and  <a class="medical medical_review" href="/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting", section on 'Pharmacotherapy'</a>.)</p><p></p><p class="headingAnchor" id="H960002921"><span class="h2">Pharmacotherapy</span><span class="headingEndMark"> — </span>No medications are recommended for routine treatment of MASLD in children [<a href="#rid9">9</a>]. Several pharmacologic approaches have been investigated in children with NAFLD including <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">vitamin E</a>, <a class="drug drug_pediatric" data-topicid="12589" href="/d/drug information/12589.html" rel="external">metformin</a>, <a class="drug drug_pediatric" data-topicid="13195" href="/d/drug information/13195.html" rel="external">cysteamine</a> bitartrate, and <a class="drug drug_pediatric" data-topicid="13047" href="/d/drug information/13047.html" rel="external">losartan</a> [<a href="#rid105">105</a>]. In clinical trials, none of these have shown a convincing advantage over lifestyle intervention alone [<a href="#rid106">106,107</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suggested for selected patients:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamin E</strong> – <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">Vitamin E</a> has a limited role in management of MASLD, based on indirect evidence that it has beneficial effects on some serologic and histologic markers of NAFLD but that prolonged high-dose treatment might be associated with adverse health outcomes in adults. In the absence of specific recommendations from guidelines [<a href="#rid9">9,10</a>], we suggest the following approach:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients who have not had liver biopsy or for those with steatosis alone (minimal inflammation), we do not advise treatment with <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">vitamin E</a>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with biopsy-proven steatohepatitis (metabolic dysfunction-associated steatohepatitis [MASH] with or without fibrosis) who are not improving with lifestyle intervention recommendations and other weight loss treatments (eg, GLP-1 receptor agonists or weight loss surgery), we suggest a trial of <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">vitamin E</a> treatment in conjunction with lifestyle changes (see <a class="local">'Weight loss-focused approaches'</a> above). The decision to treat with vitamin E is made on a case-by-case basis, after a discussion of the potential benefits and risks with the patient and family. Lifestyle modification should continue whether or not vitamin E is initiated as an adjunctive treatment. Some patients may reasonably choose to defer vitamin E treatment, given the uncertainty of clinical benefit in children.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If treatment with <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">vitamin E</a> is undertaken, we suggest a dose of 800 units daily (typically given as 400 units twice daily for children &lt;18 years). Patients should be monitored for response using serial measurements of ALT (every three months) and treatment continued only if there is evidence of response, with a significant, sustained decline in ALT (eg, at least a 50 percent decline in ALT during the first three to six months). Vitamin E is continued for up to two years. A repeat liver biopsy should be considered at the end of a two-year treatment cycle as this is the only way to assess histologic response to vitamin E and determine if there is any benefit to continuing the treatment long term. Two-year trials of vitamin E in children and adults with NAFLD reported no associated safety risks; however, the long-term safety of high-dose vitamin E in children with NAFLD/MASLD has not been established.</p><p></p><p class="bulletIndent2">The main evidence supporting <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">vitamin E</a> treatment comes from a multicenter randomized trial that included 173 children and adolescents with biopsy-proven NAFLD [<a href="#rid6">6</a>]. This study found no benefit from vitamin E (800 units daily for two years) on the primary outcome of serum aminotransferase levels. However, in a subset of 121 children with NASH, significantly more children had histologic resolution of steatohepatitis after 96 weeks of treatment with vitamin E compared with placebo (58 versus 21 percent, p&lt;0.01). No significant risks were noted during the two years of the trial. Randomized trials and observational studies in adults also suggest some benefits of vitamin E on markers of NAFLD [<a href="#rid108">108,109</a>]. However, indirect and limited evidence from observational studies in adults suggests an association between high-dose vitamin E and risk of all-cause mortality, cardiovascular events, and prostate cancer. (See  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Patients with NASH but without diabetes'</a> and  <a class="medical medical_review" href="/d/html/2582.html" rel="external">"Overview of vitamin E", section on 'Potential risks'</a>.)</p><p></p><p class="bulletIndent2">Another report suggests that <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">vitamin E</a> leads to significant reductions in ALT (&gt;50 percent from baseline or normalization) in 38 percent of children with NASH in a "real-world" setting [<a href="#rid110">110</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medications that target weight loss</strong> – Medications that target weight loss are discussed above and may lead to subsequent improvement in MASLD and MASH, though MASLD/MASH outcomes in pediatric clinical trials are largely lacking. (See <a class="local">'Weight loss-focused approaches'</a> above and  <a class="medical medical_review" href="/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting", section on 'Pharmacotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Not effective for MASLD:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metformin</strong> – <a class="drug drug_pediatric" data-topicid="12589" href="/d/drug information/12589.html" rel="external">Metformin</a> was not effective for treatment of NAFLD and is not recommended for this purpose. In the multicenter trial described above, metformin (1000 mg daily) was no more effective than placebo for outcomes of ALT elevation or histologic features of MASLD [<a href="#rid6">6</a>]. However, metformin is a first-line treatment for adolescents with type 2 diabetes. (See  <a class="medical medical_review" href="/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cysteamine</strong><strong> bitartrate</strong> – In a multicenter, placebo-controlled, randomized trial in 169 children with biopsy-confirmed steatohepatitis, treatment with <a class="drug drug_pediatric" data-topicid="13195" href="/d/drug information/13195.html" rel="external">cysteamine</a> bitartrate delayed-release for one year resulted in significant reductions in serum aminotransferase levels and lobular inflammation but no overall reduction in histologic markers of NAFLD severity, compared with placebo [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13047" href="/d/drug information/13047.html" rel="external">Losartan</a> – Losartan, an angiotensin II receptor blocker used for the treatment of hypertension, was ineffective in reducing the ALT of children and adolescents with histologically confirmed NAFLD (dose studied was 100 mg daily for 24 weeks) [<a href="#rid105">105</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – <a class="drug drug_pediatric" data-topicid="12872" href="/d/drug information/12872.html" rel="external">Ursodeoxycholic acid</a>, probiotic supplements, and omega-3 fatty acid supplements have not been shown to be effective for NAFLD in adults [<a href="#rid9">9,10</a>]. No robust clinical trials have evaluated these interventions in children.</p><p></p><p>Experience with the use of these and other drugs in adults with MASLD is discussed separately. (See  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults"</a>.)</p><p class="headingAnchor" id="H2864770775"><span class="h2">Other counseling</span></p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol and smoke exposure – Children and adolescents with MASLD should be counseled that alcohol consumption may exacerbate liver disease. Thresholds for "safe" alcohol consumption in patients with MASLD are unclear, but binge drinking or heavy alcohol use is associated with progressive disease in adults. Patients and families should also be counseled against smoking and secondhand smoke exposure [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunizations – The clinician should ensure that the patient has been immunized against hepatitis A and B by reviewing immunization records or performing serologic testing and providing immunization as needed. Because both obesity and liver disease are associated with higher risk of severe coronavirus disease 2019 (COVID-19) infection, COVID-19 vaccination should be especially encouraged for people with MASLD. (See  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sleep habits and symptoms – Sleep quality/duration is associated with obesity and response to weight loss efforts. Accordingly, we suggest counseling regarding age-appropriate sleep habits in addition to other guidance to support weight control. (See  <a class="medical medical_review" href="/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting"</a> and  <a class="medical medical_review" href="/d/html/6353.html" rel="external">"Behavioral sleep problems in children"</a>.)</p><p></p><p class="bulletIndent1">Obstructive sleep apnea (OSA) is associated with MASLD and liver fibrosis. Accordingly, children with symptoms suggesting OSA (eg, persistent snoring or mouth-breathing) should be further evaluated for OSA. If OSA is present, treatment may improve MASLD severity, although evidence is inconsistent [<a href="#rid111">111,112</a>]. (See  <a class="medical medical_review" href="/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children"</a>.)</p><p></p><p class="headingAnchor" id="H691890357"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Weight management is most successful with frequent follow-up, support, and reinforcement of healthy habits. Body weight, body mass index, and lifestyle habits should be reviewed at each visit. New comorbid conditions can emerge over time, particularly if the obesity persists or worsens; therefore, screening should be done at minimum annually  (<a class="graphic graphic_table graphicRef65547" href="/d/graphic/65547.html" rel="external">table 2</a>).</p><p>We suggest serial ALT monitoring every three to six months for patients with MASLD, especially if actively working on lifestyle modification or undergoing other treatments. We suggest annual monitoring of ALT in patients with liver steatosis alone on imaging/biopsy but with no history of liver enzyme elevations or evidence of fibrosis (on biopsy or by imaging).</p><p>This is similar to the historical approach to monitoring patients with NAFLD. In clinical trials, improvement in ALT of &gt;50 percent or complete normalization of ALT were often used as surrogate markers of improvement or resolution, respectively, because these outcomes have been associated with histologic improvement in liver disease severity in several studies [<a href="#rid39">39</a>]. However, changes in ALT should be interpreted in conjunction with the information obtained from the patient's history and physical examination.</p><p>In patients with MASH or advanced fibrosis on initial liver biopsy, or with onset of new, significant risk factors such as type 2 diabetes, we generally consider a repeat liver biopsy two to three years after diagnosis [<a href="#rid9">9</a>] to evaluate disease progression, given the limitations of noninvasive tests in children. Repeat liver biopsy may also be useful to evaluate response following intensification of treatment, such as weight loss surgery, although practice varies.</p><p class="headingAnchor" id="H3416718119"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116327.html" rel="external">"Society guideline links: Nonalcoholic fatty liver disease"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111346.html" rel="external">"Society guideline links: Obesity in children"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111575.html" rel="external">"Society guideline links: Diabetes mellitus in children"</a>.)</p><p class="headingAnchor" id="H2111230223"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Categories of steatotic liver disease associated with metabolic dysfunction are  (<a class="graphic graphic_table graphicRef115653" href="/d/graphic/115653.html" rel="external">table 1</a>) (see <a class="local">'Definitions'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metabolic dysfunction-associated steatotic liver disease (MASLD)</strong> – MASLD is the overarching term for steatotic liver disease (&gt;5 percent hepatic steatosis) with at least one risk factor for cardiometabolic dysfunction including overweight/obesity, dysglycemia, or dyslipidemia and no other cause of steatotic liver disease. This category includes individuals who would previously have been given a diagnosis of nonalcoholic fatty liver disease (NAFLD; defined by chronically elevated liver enzymes, hepatic steatosis, and absence of other causes) but also includes individuals with evidence of steatosis but without elevated liver enzymes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metabolic dysfunction-associated steatohepatitis (MASH)</strong> – MASH refers to MASLD with inflammation and hepatocellular injury, such as ballooning of hepatocytes, with or without fibrosis. This category was formerly called nonalcoholic steatohepatitis (NASH), and histologic criteria remain the same.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MASH with fibrosis or cirrhosis</strong> – Advanced fibrosis or cirrhosis with current or previous histologic evidence of MASLD or MASH.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metabolic and increased alcohol intake</strong> – MASLD with a history of increased alcohol use; it may be MASLD predominant or alcohol-related liver disease predominant depending on range of alcohol intake. This is a new category that recognizes that steatotic liver disease can involve a combination of metabolic dysfunction and alcohol. It does not include individuals with alcohol-related liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors and clinical presentation</strong> – By definition, MASLD is strongly associated with obesity and associated cardiometabolic risk factors. Predictors of more advanced disease among children with MASLD remain to be established but probably include insulin resistance, prediabetes/diabetes, and Hispanic ethnicity. Similar to NAFLD, many children with MASLD are likely to have signs or symptoms of other obesity-related comorbidities  (<a class="graphic graphic_table graphicRef65547" href="/d/graphic/65547.html" rel="external">table 2</a>). (See <a class="local">'Epidemiology'</a> above and <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – We suggest screening for MASLD for all children with obesity (body mass index ≥95<sup>th</sup> percentile), as well as for those who are overweight (body mass index ≥85<sup>th</sup> percentile) and have other risk factors (eg, signs of insulin resistance or a family history of MASLD) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef117904" href="/d/graphic/117904.html" rel="external">algorithm 1</a>). Screening should be initiated between 9 and 11 years. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Method</strong> – We screen for MASLD by measuring serum alanine aminotransferase (ALT) to detect children at higher risk of more significant liver disease. Under prior diagnostic criteria for NAFLD, most children had liver enzymes &gt;2 times the upper limit of normal (ULN), but some had more markedly elevated liver enzymes (but rarely &gt;5 times the ULN). There is insufficient evidence to recommend universal screening of at-risk children by imaging modalities, outside of research studies. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further evaluation</strong> – Patients with suspected MASLD and persistent elevations of serum ALT (&gt;2 times the ULN for &gt;3 months) should be further evaluated to exclude other causes of liver disease through a focused history, physical examination, and laboratory evaluation  (<a class="graphic graphic_algorithm graphicRef117904" href="/d/graphic/117904.html" rel="external">algorithm 1</a>). The timing and extent of the evaluation depends on the degree of ALT elevation and whether any atypical features are present. (See <a class="local">'Further evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A provisional diagnosis of MASLD can be made by excluding other causes of liver disease through a focused clinical evaluation  (<a class="graphic graphic_table graphicRef116582" href="/d/graphic/116582.html" rel="external">table 4</a>). A definitive diagnosis of MASH can only be made by liver biopsy, but this is not always necessary for initial clinical management. Histologic assessment of severity of disease can help guide therapeutic decisions such as whether to treat with <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">vitamin E</a> or to intensify weight management approaches, including considering weight loss medications or weight loss surgery for selected patients with more advanced disease. (See <a class="local">'Liver biopsy'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Weight loss</strong> – The mainstays of treatment for MASLD are interventions to reduce overweight and obesity. The first-line approach in youth is counseling directed at improving diet (reduction in added sugars and ultraprocessed foods) and exercise habits (increasing moderate to vigorous activity). These interventions can reduce visceral adiposity and hepatic steatosis, as well as provide other general health benefits and also may be beneficial for individuals with MASLD but without obesity. Weight loss surgery or obesity-directed pharmacotherapy (eg, a glucagon-like peptide 1 [GLP-1] receptor agonist) may be appropriate for selected adolescents with moderate or severe obesity, especially if liver biopsy shows evidence of advanced MASLD. (See <a class="local">'Weight loss-focused approaches'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacotherapy</strong> – <a class="drug drug_pediatric" data-topicid="12884" href="/d/drug information/12884.html" rel="external">Vitamin E</a> has a limited role in management of MASLD. For patients with biopsy-proven MASH (with or without fibrosis) who have not improved with lifestyle interventions alone and who are not candidates for other weight loss treatments (eg, GLP-1 receptor agonists or weight loss surgery), we suggest a trial of vitamin E (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If serum ALT improves, we continue vitamin E for a period of up to two years. Limited evidence suggests that high-dose vitamin E improves some markers of MASH but that long-term treatment may be associated with adverse cardiovascular outcomes. Vitamin E does not play a role in management for patients who have not had liver biopsy or for those with steatosis alone (minimal inflammation). (See <a class="local">'Pharmacotherapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78:1966.</a></li><li><a class="nounderline abstract_t">Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004; 8:549.</a></li><li><a class="nounderline abstract_t">Huang JS, Barlow SE, Quiros-Tejeira RE, et al. Childhood obesity for pediatric gastroenterologists. J Pediatr Gastroenterol Nutr 2013; 56:99.</a></li><li><a class="nounderline abstract_t">Anderson EL, Howe LD, Jones HE, et al. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One 2015; 10:e0140908.</a></li><li><a class="nounderline abstract_t">Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58:1538.</a></li><li><a class="nounderline abstract_t">Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305:1659.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Lavine JE, Wilson LA, et al. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology 2016; 151:1141.</a></li><li><a class="nounderline abstract_t">Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77:1797.</a></li><li><a class="nounderline abstract_t">Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017; 64:319.</a></li><li><a class="nounderline abstract_t">Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67:328.</a></li><li><a class="nounderline abstract_t">Patel KR, White FV, Deutsch GH. Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus. J Pediatr Gastroenterol Nutr 2015; 60:152.</a></li><li><a class="nounderline abstract_t">Kinugasa A, Tsunamoto K, Furukawa N, et al. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984; 3:408.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118:1388.</a></li><li><a class="nounderline abstract_t">Fernandes DM, Pantangi V, Azam M, et al. Pediatric Nonalcoholic Fatty Liver Disease in New York City: An Autopsy Study. J Pediatr 2018; 200:174.</a></li><li><a class="nounderline abstract_t">Montinaro F, Busby GB, Pascali VL, et al. Unravelling the hidden ancestry of American admixed populations. Nat Commun 2015; 6:6596.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Newton KP, Awai HI, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 38:1267.</a></li><li><a class="nounderline abstract_t">Mischel AK, Liao Z, Cao F, et al. Prevalence of Elevated ALT in Adolescents in the US 2011-2018. J Pediatr Gastroenterol Nutr 2023; 77:103.</a></li><li><a class="nounderline abstract_t">Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013; 162:496.</a></li><li><a class="nounderline abstract_t">Awai HI, Newton KP, Sirlin CB, et al. Evidence and recommendations for imaging liver fat in children, based on systematic review. Clin Gastroenterol Hepatol 2014; 12:765.</a></li><li><a class="nounderline abstract_t">Speiser PW, Rudolf MC, Anhalt H, et al. Childhood obesity. J Clin Endocrinol Metab 2005; 90:1871.</a></li><li><a class="nounderline abstract_t">Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413.</a></li><li><a class="nounderline abstract_t">Mandato C, Lucariello S, Licenziati MR, et al. Metabolic, hormonal, oxidative, and inflammatory factors in pediatric obesity-related liver disease. J Pediatr 2005; 147:62.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Deutsch R, Rauch JB, et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143:500.</a></li><li><a class="nounderline abstract_t">Newton KP, Hou J, Crimmins NA, et al. Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. JAMA Pediatr 2016; 170:e161971.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Zepeda A, Newton KP, et al. Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS One 2014; 9:e112569.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Pardee PE, Lavine JE, et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008; 118:277.</a></li><li><a class="nounderline abstract_t">Zhang H, Yang H, Lai C, et al. Quantitative relationship between liver fat content and metabolic syndrome in obese children and adolescents. Clin Endocrinol (Oxf) 2015; 83:43.</a></li><li><a class="nounderline abstract_t">Nobili V, Cutrera R, Liccardo D, et al. Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med 2014; 189:66.</a></li><li><a class="nounderline abstract_t">Conjeevaram Selvakumar PK, Kabbany MN, Lopez R, et al. Prevalence of Suspected Nonalcoholic Fatty Liver Disease in Lean Adolescents in the United States. J Pediatr Gastroenterol Nutr 2018; 67:75.</a></li><li><a class="nounderline abstract_t">Stanislawski MA, Shaw J, Litkowski E, et al. Genetic Risk for Hepatic Fat among an Ethnically Diverse Cohort of Youth: The Exploring Perinatal Outcomes among Children Study. J Pediatr 2020; 220:146.</a></li><li><a class="nounderline abstract_t">Namjou B, Lingren T, Huang Y, et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med 2019; 17:135.</a></li><li><a class="nounderline abstract_t">Hagström H, Simon TG, Roelstraete B, et al. Maternal obesity increases the risk and severity of NAFLD in offspring. J Hepatol 2021; 75:1042.</a></li><li><a class="nounderline abstract_t">Yang Y, Qi ZR, Zhang TT, et al. Rapidly progressive non-alcoholic fatty liver disease due to hypopituitarism. Report of 5 cases. Neuro Endocrinol Lett 2018; 39:99.</a></li><li><a class="nounderline abstract_t">Yodoshi T, Orkin S, Arce Clachar AC, et al. Muscle Mass Is Linked to Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease. J Pediatr 2020; 223:93.</a></li><li><a class="nounderline abstract_t">Pacifico L, Perla FM, Andreoli G, et al. Nonalcoholic Fatty Liver Disease Is Associated With Low Skeletal Muscle Mass in Overweight/Obese Youths. Front Pediatr 2020; 8:158.</a></li><li><a class="nounderline abstract_t">Marzuillo P, Miraglia del Giudice E, Santoro N. Pediatric fatty liver disease: role of ethnicity and genetics. World J Gastroenterol 2014; 20:7347.</a></li><li><a class="nounderline abstract_t">Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77:1335.</a></li><li><a class="nounderline abstract_t">Talens M, Tumas N, Lazarus JV, et al. What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Xanthakos SA, Lavine JE, Yates KP, et al. Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. Gastroenterology 2020; 159:1731.</a></li><li><a class="nounderline abstract_t">Simon TG, Roelstraete B, Hartjes K, et al. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J Hepatol 2021; 75:1034.</a></li><li><a class="nounderline abstract_t">Baldridge AD, Perez-Atayde AR, Graeme-Cook F, et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127:700.</a></li><li><a class="nounderline abstract_t">Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30:48.</a></li><li><a class="nounderline abstract_t">Phatak UP, Pashankar DS. Obesity and gastrointestinal disorders in children. J Pediatr Gastroenterol Nutr 2015; 60:441.</a></li><li><a class="nounderline abstract_t">Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42:1428.</a></li><li><a class="nounderline abstract_t">Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Serum alanine aminotransferase activity in obese children. Acta Paediatr 1997; 86:238.</a></li><li><a class="nounderline abstract_t">Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125:239.</a></li><li><a class="nounderline abstract_t">Ezaizi Y, Kabbany MN, Conjeevaram Selvakumar PK, et al. Comparison between non-alcoholic fatty liver disease screening guidelines in children and adolescents. JHEP Rep 2019; 1:259.</a></li><li><a class="nounderline abstract_t">Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013; 33:1398.</a></li><li><a class="nounderline abstract_t">Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012; 54:700.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138:1357.</a></li><li><a class="nounderline abstract_t">Bussler S, Vogel M, Pietzner D, et al. New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage. Hepatology 2018; 68:1319.</a></li><li><a class="nounderline abstract_t">Shaw JL, Cohen A, Konforte D, et al. Validity of establishing pediatric reference intervals based on hospital patient data: a comparison of the modified Hoffmann approach to CALIPER reference intervals obtained in healthy children. Clin Biochem 2014; 47:166.</a></li><li><a class="nounderline abstract_t">Rich NE, Oji S, Mufti AR, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16:198.</a></li><li><a class="nounderline abstract_t">Sundaram SS, Sokol RJ, Capocelli KE, et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J Pediatr 2014; 164:699.</a></li><li><a class="nounderline abstract_t">Molleston JP, Schwimmer JB, Yates KP, et al. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014; 164:707.</a></li><li><a class="nounderline abstract_t">Shannon A, Alkhouri N, Carter-Kent C, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr 2011; 53:190.</a></li><li><a class="nounderline abstract_t">Bohte AE, Koot BG, van der Baan-Slootweg OH, et al. US cannot be used to predict the presence or severity of hepatic steatosis in severely obese adolescents. Radiology 2012; 262:327.</a></li><li><a class="nounderline abstract_t">Noon SL, D'Annibale DA, Schwimmer MH, et al. Incidence of Depression and Anxiety in a Cohort of Adolescents With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 2021; 72:579.</a></li><li><a class="nounderline abstract_t">Pacifico L, Bonci E, Andreoli GM, et al. The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity. Int J Mol Sci 2016; 17.</a></li><li><a class="nounderline abstract_t">Yodoshi T, Arce-Clachar AC, Sun Q, et al. Glomerular Hyperfiltration Is Associated with Liver Disease Severity in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 2020; 222:127.</a></li><li><a class="nounderline abstract_t">Targher G, Mantovani A, Alisi A, et al. Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. Hepatology 2019; 70:142.</a></li><li><a class="nounderline abstract_t">Mantovani A, Gatti D, Zoppini G, et al. Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis. Hepatology 2019; 70:812.</a></li><li><a class="nounderline abstract_t">Yodoshi T, Orkin S, Arce-Clachar AC, et al. Alternative Etiologies of Liver Disease in Children With Suspected NAFLD. Pediatrics 2021; 147.</a></li><li><a class="nounderline abstract_t">Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2004; 99:1316.</a></li><li><a class="nounderline abstract_t">Vuppalanchi R, Gould RJ, Wilson LA, et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2012; 6:379.</a></li><li><a class="nounderline abstract_t">Khayat A, Vitola B. Prevalence and Clinical Significance of Autoantibodies in Children with Overweight and Obesity with Nonalcoholic Fatty Liver Disease. J Pediatr 2021; 239:155.</a></li><li><a class="nounderline abstract_t">Regev A, Guaqueta C, Molina EG, et al. Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study. J Pediatr Gastroenterol Nutr 2006; 43 Suppl 1:S30.</a></li><li><a class="nounderline abstract_t">Valenti L, Dongiovanni P, Piperno A, et al. Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology 2006; 44:857.</a></li><li><a class="nounderline abstract_t">Burton BK, Deegan PB, Enns GM, et al. Clinical Features of Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2015; 61:619.</a></li><li><a class="nounderline abstract_t">Zhang B, Porto AF. Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr 2013; 56:682.</a></li><li><a class="nounderline abstract_t">Bernstein DL, Hülkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol 2013; 58:1230.</a></li><li><a class="nounderline abstract_t">Maciejko JJ, Anne P, Raza S, Lyons HJ. Lysosomal acid lipase deficiency in all siblings of the same parents. J Clin Lipidol 2017; 11:567.</a></li><li><a class="nounderline abstract_t">Valayannopoulos V, Mengel E, Brassier A, Grabowski G. Lysosomal acid lipase deficiency: Expanding differential diagnosis. Mol Genet Metab 2017; 120:62.</a></li><li><a class="nounderline abstract_t">Himes RW, Barlow SE, Bove K, et al. Lysosomal Acid Lipase Deficiency Unmasked in Two Children With Nonalcoholic Fatty Liver Disease. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Hamilton J, Jones I, Srivastava R, Galloway P. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta 2012; 413:1207.</a></li><li><a class="nounderline abstract_t">Burton BK, Balwani M, Feillet F, et al. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med 2015; 373:1010.</a></li><li><a class="nounderline abstract_t">Jones SA, Rojas-Caro S, Quinn AG, et al. Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. Orphanet J Rare Dis 2017; 12:25.</a></li><li class="breakAll">US Food and Drug Administration: FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476013.htm (Accessed on November 20, 2017).</li><li><a class="nounderline abstract_t">Lyons H, Vouyoukas E, Higgins M, Maciejko JJ. Clinical and Histologic Liver Improvement in Siblings With Lysosomal Acid Lipase Deficiency After Enzyme Replacement. J Pediatr Gastroenterol Nutr 2020; 70:635.</a></li><li><a class="nounderline abstract_t">Burton BK, Feillet F, Furuya KN, et al. Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study. J Hepatol 2022; 76:577.</a></li><li><a class="nounderline abstract_t">Burton BK, Sanchez AC, Kostyleva M, et al. Long-Term Sebelipase Alfa Treatment in Children and Adults With Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2022; 74:757.</a></li><li><a class="nounderline abstract_t">Peretti N, Sassolas A, Roy CC, et al. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. Orphanet J Rare Dis 2010; 5:24.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Middleton MS, Behling C, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology 2015; 61:1887.</a></li><li><a class="nounderline abstract_t">Kohli R, Sunduram S, Mouzaki M, et al. Pediatric Nonalcoholic Fatty Liver Disease: A Report from the Expert Committee on Nonalcoholic Fatty Liver Disease (ECON). J Pediatr 2016; 172:9.</a></li><li><a class="nounderline abstract_t">Yu EL, Golshan S, Harlow KE, et al. Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity. J Pediatr 2019; 207:64.</a></li><li><a class="nounderline abstract_t">Baker S, Barlow S, Cochran W, et al. Overweight children and adolescents: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:533.</a></li><li><a class="nounderline abstract_t">McNair A. Non-alcoholic steatohepatitis (NASH): why biopsy? Gut 2002; 51:898; author reply 898.</a></li><li><a class="nounderline abstract_t">Chaidez A, Pan Z, Sundaram SS, et al. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children. Hepatol Commun 2022; 6:3015.</a></li><li><a class="nounderline abstract_t">Garcovich M, Veraldi S, Di Stasio E, et al. Liver Stiffness in Pediatric Patients with Fatty Liver Disease: Diagnostic Accuracy and Reproducibility of Shear-Wave Elastography. Radiology 2017; 283:820.</a></li><li><a class="nounderline abstract_t">Mandelia C, Kabbany MN, Worley S, Conjeevaram Selvakumar PK. Performance Characteristics, Intra- and Inter-operator Agreement of Transient Elastography in Pediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 2021; 72:430.</a></li><li><a class="nounderline abstract_t">Alkhouri N, Sedki E, Alisi A, et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int 2013; 33:79.</a></li><li><a class="nounderline abstract_t">Brunnert L, Puasa ID, Garten A, et al. Pediatric percentiles for transient elastography measurements - effects of age, sex, weight status and pubertal stage. Front Endocrinol (Lausanne) 2022; 13:1030809.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Behling C, Angeles JE, et al. Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. Hepatology 2017; 66:1474.</a></li><li><a class="nounderline abstract_t">Mouzaki M, Trout AT, Arce-Clachar AC, et al. Assessment of Nonalcoholic Fatty Liver Disease Progression in Children Using Magnetic Resonance Imaging. J Pediatr 2018; 201:86.</a></li><li><a class="nounderline abstract_t">Xanthakos SA, Podberesky DJ, Serai SD, et al. Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. J Pediatr 2014; 164:186.</a></li><li><a class="nounderline abstract_t">Dillman JR, Trout AT, Costello EN, et al. Quantitative Liver MRI-Biopsy Correlation in Pediatric and Young Adult Patients With Nonalcoholic Fatty Liver Disease: Can One Be Used to Predict the Other? AJR Am J Roentgenol 2018; 210:166.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42:641.</a></li><li><a class="nounderline abstract_t">Suzuki A, Abdelmalek MF, Schwimmer JB, et al. Association between puberty and features of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012; 10:786.</a></li><li><a class="nounderline abstract_t">Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100:1072.</a></li><li><a class="nounderline abstract_t">Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child 2009; 94:437.</a></li><li><a class="nounderline abstract_t">Pozzato C, Verduci E, Scaglioni S, et al. Liver fat change in obese children after a 1-year nutrition-behavior intervention. J Pediatr Gastroenterol Nutr 2010; 51:331.</a></li><li><a class="nounderline abstract_t">Schwimmer JB, Ugalde-Nicalo P, Welsh JA, et al. Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial. JAMA 2019; 321:256.</a></li><li><a class="nounderline abstract_t">Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics 2023; 151.</a></li><li><a class="nounderline abstract_t">Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006; 44:458.</a></li><li><a class="nounderline abstract_t">Vos MB, Van Natta ML, Blondet NM, et al. Randomized placebo-controlled trial of losartan for pediatric NAFLD. Hepatology 2022; 76:429.</a></li><li><a class="nounderline abstract_t">Nobili V, Manco M, Ciampalini P, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008; 30:1168.</a></li><li><a class="nounderline abstract_t">Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48:119.</a></li><li><a class="nounderline abstract_t">Sato K, Gosho M, Yamamoto T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition 2015; 31:923.</a></li><li><a class="nounderline abstract_t">Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology 2020; 71:495.</a></li><li><a class="nounderline abstract_t">Yodoshi T, Orkin S, Arce-Clachar AC, et al. Identifying Predictors of Response to Vitamin E for the Treatment of Pediatric Nonalcoholic Steatohepatitis. JPEN J Parenter Enteral Nutr 2020; 44:1301.</a></li><li><a class="nounderline abstract_t">Sundaram SS, Halbower AC, Klawitter J, et al. Treating Obstructive Sleep Apnea and Chronic Intermittent Hypoxia Improves the Severity of Nonalcoholic Fatty Liver Disease in Children. J Pediatr 2018; 198:67.</a></li><li><a class="nounderline abstract_t">Ng SSS, Wong VWS, Wong GLH, et al. Continuous Positive Airway Pressure Does Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea. A Randomized Clinical Trial. Am J Respir Crit Care Med 2021; 203:493.</a></li></ol></div><div id="topicVersionRevision">Topic 115661 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37363821" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A multisociety Delphi consensus statement on new fatty liver disease nomenclature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331063" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nonalcoholic fatty liver disease in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23282941" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Childhood obesity for pediatric gastroenterologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26512983" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19625277" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521847" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27569726" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36727674" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28107283" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28714183" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25079479" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6737186" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fatty liver and its fibrous changes found in simple obesity of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015527" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of fatty liver in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29903531" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pediatric Nonalcoholic Fatty Liver Disease in New York City: An Autopsy Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25803618" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Unravelling the hidden ancestry of American admixed populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24117728" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37084344" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence of Elevated ALT in Adolescents in the US 2011-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23084707" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24090729" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evidence and recommendations for imaging liver fat in children, based on systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598688" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Childhood obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348825" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027697" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Metabolic, hormonal, oxidative, and inflammatory factors in pediatric obesity-related liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14571229" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27478956" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25419656" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591439" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25711346" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Quantitative relationship between liver fat content and metabolic syndrome in obese children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24256086" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29570139" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevalence of Suspected Nonalcoholic Fatty Liver Disease in Lean Adolescents in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32143931" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Genetic Risk for Hepatic Fat among an Ethnically Diverse Cohort of Youth: The Exploring Perinatal Outcomes among Children Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31311600" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34289397" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Maternal obesity increases the risk and severity of NAFLD in offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30183204" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rapidly progressive non-alcoholic fatty liver disease due to hypopituitarism. Report of 5 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32711755" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Muscle Mass Is Linked to Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32351917" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nonalcoholic Fatty Liver Disease Is Associated With Low Skeletal Muscle Mass in Overweight/Obese Youths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24966605" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pediatric fatty liver disease: role of ethnicity and genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36626630" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34768539" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32712103" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34224779" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7472819" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Idiopathic steatohepatitis in childhood: a multicenter retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10630439" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Nonalcoholic steatohepatitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25493349" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Obesity and gastrointestinal disorders in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9246041" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9099310" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Serum alanine aminotransferase activity in obese children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8040771" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Persistent hyperaminotransferasemia resolving after weight reduction in obese children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32039376" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Comparison between non-alcoholic fatty liver disease screening guidelines in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23763360" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395188" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20064512" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28926121" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase,γ-glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24316101" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Validity of establishing pediatric reference intervals based on hospital patient data: a comparison of the modified Hoffmann approach to CALIPER reference intervals obtained in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28970148" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24321532" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24360992" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21788761" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22106358" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : US cannot be used to predict the presence or severity of hepatic steatosis in severely obese adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346572" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Incidence of Depression and Anxiety in a Cohort of Adolescents With Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27472326" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32381466" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Glomerular Hyperfiltration Is Associated with Liver Disease Severity in Children with Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30912854" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30706504" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33785637" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Alternative Etiologies of Liver Disease in Children With Suspected NAFLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15233671" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21557024" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34454951" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prevalence and Clinical Significance of Autoantibodies in Children with Overweight and Obesity with Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16819398" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17006922" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26252914" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical Features of Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23403440" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23485521" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28502515" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Lysosomal acid lipase deficiency in all siblings of the same parents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27876313" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Lysosomal acid lipase deficiency: Expanding differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27624512" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Lysosomal Acid Lipase Deficiency Unmasked in Two Children With Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22483793" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26352813" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28179030" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28179030" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32097366" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical and Histologic Liver Improvement in Siblings With Lysosomal Acid Lipase Deficiency After Enzyme Replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34774639" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35442238" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-Term Sebelipase Alfa Treatment in Children and Adults With Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20920215" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25529941" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26749112" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pediatric Nonalcoholic Fatty Liver Disease: A Report from the Expert Committee on Nonalcoholic Fatty Liver Disease (ECON).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559024" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15861011" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Overweight children and adolescents: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427803" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Non-alcoholic steatohepatitis (NASH): why biopsy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36069338" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27982761" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Liver Stiffness in Pediatric Patients with Fatty Liver Disease: Diagnostic Accuracy and Reproducibility of Shear-Wave Elastography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33230078" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Performance Characteristics, Intra- and Inter-operator Agreement of Transient Elastography in Pediatric Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23146095" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36237190" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Pediatric percentiles for transient elastography measurements - effects of age, sex, weight status and pubertal stage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28493388" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30041934" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Assessment of Nonalcoholic Fatty Liver Disease Progression in Children Using Magnetic Resonance Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064151" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29045180" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Quantitative Liver MRI-Biopsy Correlation in Pediatric and Young Adult Patients With Nonalcoholic Fatty Liver Disease: Can One Be Used to Predict the Other?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116629" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Histopathology of pediatric nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343513" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Association between puberty and features of nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842581" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224892" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20562718" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Liver fat change in obese children after a 1-year nutrition-behavior intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30667502" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36622115" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871574" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35133671" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Randomized placebo-controlled trial of losartan for pediatric NAFLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18640473" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18537181" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26059365" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30506586" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31985850" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Identifying Predictors of Response to Vitamin E for the Treatment of Pediatric Nonalcoholic Steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29752170" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Treating Obstructive Sleep Apnea and Chronic Intermittent Hypoxia Improves the Severity of Nonalcoholic Fatty Liver Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926803" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Continuous Positive Airway Pressure Does Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea. A Randomized Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
